Sumitomo Chemical Company (4005) Status Update summary

Strategic Business Focus and Growth Initiatives

• Emphasis on strengthening core businesses rooted in organic synthesis technology, particularly in agro and life solutions, ICT/mobility solutions, and advanced medical solutions, with a focus on technological advantages for growth and resilience.

• Crop protection products Indiflin, Rapidacil, and Pavechto are positioned as future blockbuster chemicals, with significant R&D achievements, global market expansion plans, and sales growth expected by 2030.

• Expansion in semiconductor materials, high-purity chemicals, and OLED display materials, leveraging proprietary technology, global manufacturing sites, and targeting a 20% share in cutting-edge resists with doubled sales by 2030.

• Regenerative medicine and cell therapy identified as new growth drivers, focusing on iPS cell-based therapies, CDMO business, and blockbuster status for Parkinson’s disease therapy, with NDA filed in Japan and US trials underway.

• Structural reforms include divestment from commodity resin businesses, integration of Prime Polymer, financial improvement plans for Petro Rabigh, and a shift to high value-added, eco-friendly products.

Financial and Capital Efficiency Improvements

• Medium-term targets set for core operating income of ¥200 billion, ROE of 8%, ROIC of 6%, and D/E ratio of 0.8x, with a focus on ROIC-oriented management and enterprise value enhancement.

• Strengthening investment management through data-driven, objective, and agile processes to enhance capital efficiency and reduce impairment risk.

• Shareholder returns targeted at a payout ratio over 30% and annual dividend of ¥24 per share or more, contingent on achieving financial goals.

Market and Competitive Landscape

• AGL (agro and life solutions) business faces cyclical challenges in key markets like Brazil, North America, and India, with strategies to manage inventory and tariffs.

• Chinese competitors are recognized as both a threat and potential partners, especially in advanced technology sectors; innovation and differentiation are prioritized.

• Biorational and biostimulant segments are targeted for expansion, particularly in Europe and South America, possibly through acquisitions and aiming to double business scale by 2030.